Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 23 2024 - 8:00AM
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage
biotechnology company pioneering the development of novel oncolytic
immunotherapies, today announced that members of the Replimune
management team will present at the 43rd Annual J.P. Morgan
Healthcare Conference on Monday, January 13, 2025 at 2:15 PM PT.
A simultaneous webcast will be available in the Investors
section of Replimune’s website at replimune.com. A replay will be
available for 30 days following the conference.
About Replimune Replimune
Group, Inc., headquartered in Woburn, MA, was founded in 2015 with
the mission to transform cancer treatment by pioneering the
development of novel oncolytic immunotherapies. Replimune’s
proprietary RPx platform is based on a potent HSV-1 backbone
intended to maximize immunogenic cell death and the induction of a
systemic anti-tumor immune response. The RPx platform is designed
to have unique dual local and systemic activity consisting of
direct selective virus-mediated killing of the tumor resulting in
the release of tumor derived antigens and altering of the tumor
microenvironment to ignite a strong and durable systemic response.
The RPx product candidates are expected to be synergistic with most
established and experimental cancer treatment modalities, leading
to the versatility to be developed alone or combined with a variety
of other treatment options. For more information, please visit
replimune.com.
Investor InquiriesChris BrinzeyICR
Healthcare339.970.2843chris.brinzey@icrhealthcare.com
Media InquiriesArleen
GoldenbergReplimune917.548.1582media@replimune.com
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Dec 2024 to Jan 2025
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Jan 2024 to Jan 2025